Cladribine (BioDeep_00000018072)

   

human metabolite blood metabolite Chemicals and Drugs Cytotoxicity


代谢物信息卡片


(2R,3S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol

化学式: C10H12ClN5O3 (285.06286320000004)
中文名称: 克拉利宾
谱图信息: 最多检出来源 Homo sapiens(urine) 50%

分子结构信息

SMILES: C1C(C(OC1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
InChI: InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1

描述信息

Cladribine is only found in individuals that have used or taken this drug. It is an antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. [PubChem]Cladribine is structurally related to fludarabine and pentostatin but has a different mechanism of action. Although the exact mechanism of action has not been fully determined, evidence shows that cladribine is phosphorylated by deoxycytidine kinase to the nucleotidecladribine triphosphate (CdATP; 2-chloro-2′-deoxyadenosine 5′-triphosphate), which accumulates and is incorporated into DNA in cells such as lymphocytes that contain high levels of deoxycytidine kinase and low levels of deoxynucleotidase, resulting in DNA strand breakage and inhibition of DNA synthesis and repair. High levels of CdATP also appear to inhibit ribonucleotide reductase, which leads to an imbalance in triphosphorylated deoxynucleotide (dNTP) pools and subsequent DNA strand breaks, inhibition of DNA synthesis and repair, nicotinamide adenine dinucleotide (NAD) and ATP depletion, and cell death. Unlike other antimetabolite drugs, cladribine has cytotoxic effects on resting as well as proliferating lymphocytes. However, it does cause cells to accumulate at the G1/S phase junction, suggesting that cytotoxicity is associated with events critical to cell entry into S phase. It also binds purine nucleoside phosphorylase (PNP), however no relationship between this binding and a mechanism of action has been established.
L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants > L04AA - Selective immunosuppressants
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BB - Purine analogues
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite
D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents
C471 - Enzyme Inhibitor > C2157 - Adenosine Deaminase Inhibitor
C274 - Antineoplastic Agent > C798 - Radiosensitizing Agent
D000970 - Antineoplastic Agents
Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis[1][2].

同义名列表

24 个代谢物同义名

(2R,3S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; (2R,3S,5R)-5-(6-Amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; 2-Chloro-6-amino-9-(2-deoxy-b-D-erythro-pentofuranosyl)purine; 2-Chloro-6-amino-9-(2-deoxy-β-D-erythro-pentofuranosyl)purine; 2-Chloro-2-deoxy-beta-adenosine; 2-Chloro-2-deoxy-β-adenosine; 2-Chloro-2-deoxy-b-adenosine; 2-Chloro-2-deoxyadenosine; 2-Deoxy-2-chloroadenosine; 2-Chloro-deoxyadenosine; 2-Chlorodeoxyadenosine; Chlorodeoxyadenosine; Cladribinum; CHEMBL17639; Cladribine; Cladribina; Mavenclad; Leustatin; CldAdo; 2ClAdo; 2-CdA; 2-Chloro-2′-deoxyadenosine; 2CdA



数据库引用编号

13 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Khadga Raj Aran, G D Gupta, Shamsher Singh. Cladribine Induces Apoptosis, Neuroinflammation, Mitochondrial Oxidative Stress, Tau Phosphorylation and Aβ (1-42) Pathway in the Hippocampus: An In vivo Approach. Journal of chemical neuroanatomy. 2023 Sep; ?(?):102340. doi: 10.1016/j.jchemneu.2023.102340. [PMID: 37708945]
  • Lin Liu, Yeqiang Xia, Yingchen Li, Yong Zhou, Xiaofeng Su, Xiaojing Yan, Yan Wang, Wende Liu, Hongmei Cheng, Yuanchao Wang, Qing Yang. Inhibition of chitin deacetylases to attenuate plant fungal diseases. Nature communications. 2023 06; 14(1):3857. doi: 10.1038/s41467-023-39562-7. [PMID: 37385996]
  • Livnat Brill, Ariel Rechtman, Alla Shifrin, Ayal Rozenberg, Svetlana Afanasiev, Omri Zveik, Nitzan Haham, Neta Levin, Adi Vaknin-Dembinsky. Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine. Multiple sclerosis and related disorders. 2022 Jul; 63(?):103863. doi: 10.1016/j.msard.2022.103863. [PMID: 35667316]
  • Ayalew Tefferi, Jaya Kittur, Faiqa Farrukh, Kebede H Begna, Mrinal M Patnaik, Aref Al-Kali, Michelle A Elliott, Kaaren K Reichard, Naseema Gangat, Animesh Pardanani. Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. British journal of haematology. 2022 02; 196(4):975-983. doi: 10.1111/bjh.17932. [PMID: 34729775]
  • David Baker, Amy MacDougall, Angray S Kang, Klaus Schmierer, Gavin Giovannoni, Ruth Dobson. CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. Multiple sclerosis and related disorders. 2022 Jan; 57(?):103448. doi: 10.1016/j.msard.2021.103448. [PMID: 34902760]
  • Doriana Landi, Carolina Gabri Nicoletti, Giovanni Di Mauro, Gaia Cola, Alfonso Grimaldi, Giorgia Mataluni, Girolama Alessandra Marfia. Anti-HBs titers are not decreased after treatment with oral Cladribine in patients with Multiple Sclerosis vaccinated against Hepatitis B virus. Multiple sclerosis and related disorders. 2022 Jan; 57(?):103334. doi: 10.1016/j.msard.2021.103334. [PMID: 35158447]
  • Livnat Brill, Ariel Rechtman, Omri Zveik, Nitzan Haham, Netta Levin, Alla Shifrin, Ayal Rozenberg, Adi Vaknin-Dembinsky. Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis. Multiple sclerosis and related disorders. 2022 Jan; 57(?):103343. doi: 10.1016/j.msard.2021.103343. [PMID: 35158452]
  • Nitsan Haham, Adi Vaknin-Dembinsky. COVID-19 in Cladribine-treated patient with multiple sclerosis. Journal of neuroimmunology. 2021 10; 359(?):577690. doi: 10.1016/j.jneuroim.2021.577690. [PMID: 34390951]
  • Maria Pia Sormani, Matilde Inglese, Irene Schiavetti, Luca Carmisciano, Alice Laroni, Caterina Lapucci, Giorgio Da Rin, Carlo Serrati, Ilaria Gandoglia, Tiziana Tassinari, Germana Perego, Giampaolo Brichetto, Paola Gazzola, Antonio Mannironi, Maria Laura Stromillo, Cinzia Cordioli, Doriana Landi, Marinella Clerico, Elisabetta Signoriello, Jessica Frau, Maria Teresa Ferrò, Alessia Di Sapio, Livia Pasquali, Monica Ulivelli, Fabiana Marinelli, Graziella Callari, Rosa Iodice, Giuseppe Liberatore, Francesca Caleri, Anna Maria Repice, Susanna Cordera, Mario Alberto Battaglia, Marco Salvetti, Diego Franciotta, Antonio Uccelli. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine. 2021 Oct; 72(?):103581. doi: 10.1016/j.ebiom.2021.103581. [PMID: 34563483]
  • Meral Seferoğlu, Özlem Ethemoğlu, Ömer Faruk Turan, Aksel Siva. MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2021 Sep; 42(9):3533-3535. doi: 10.1007/s10072-021-05409-6. [PMID: 34165650]
  • Paolo Preziosa, Maria A Rocca, Agostino Nozzolillo, Lucia Moiola, Massimo Filippi. COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience. Journal of neurology. 2021 Aug; 268(8):2697-2699. doi: 10.1007/s00415-020-10309-4. [PMID: 33216223]
  • Fabio Buttari, Antonio Bruno, Ettore Dolcetti, Federica Azzolini, Paolo Bellantonio, Diego Centonze, Roberta Fantozzi. COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab. Multiple sclerosis and related disorders. 2021 Jul; 52(?):102983. doi: 10.1016/j.msard.2021.102983. [PMID: 33990054]
  • Dominic Jack, Doris Damian, Axel Nolting, Andrew Galazka. COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update. Multiple sclerosis and related disorders. 2021 Jun; 51(?):102929. doi: 10.1016/j.msard.2021.102929. [PMID: 33813097]
  • Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
  • Stefano Gelibter, Mario Orrico, Massimo Filippi, Lucia Moiola. COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?. Multiple sclerosis and related disorders. 2021 04; 49(?):102775. doi: 10.1016/j.msard.2021.102775. [PMID: 33517176]
  • Rui-Hua Mi, Lin Chen, Hai-Ping Yang, Xian-Jing Wang, Shu-Li Guo, Lin Shi, Qing-Song Yin, Xu-Dong Wei. [CLAG Regimen Composed of Continuous Intravenous Infusion of Cladribine in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia]. Zhongguo shi yan xue ye xue za zhi. 2021 Apr; 29(2):333-338. doi: 10.19746/j.cnki.issn.1009-2137.2021.02.005. [PMID: 33812396]
  • Anthony T Reder, Diego Centonze, Maria L Naylor, Anjali Nagpal, Rajani Rajbhandari, Arman Altincatal, Michelle Kim, Aaron Berdofe, Maha Radhakrishnan, Eunice Jung, Alfred W Sandrock, Karen Smirnakis, Catrinel Popescu, Carl de Moor. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS drugs. 2021 03; 35(3):317-330. doi: 10.1007/s40263-021-00804-1. [PMID: 33743151]
  • Dominic Jack, Axel Nolting, Andrew Galazka. Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets. Multiple sclerosis and related disorders. 2020 11; 46(?):102469. doi: 10.1016/j.msard.2020.102469. [PMID: 32919180]
  • Elisabeth G Celius. Normal antibody response after COVID-19 during treatment with cladribine. Multiple sclerosis and related disorders. 2020 Nov; 46(?):102476. doi: 10.1016/j.msard.2020.102476. [PMID: 32882501]
  • Mai M Anwar. Immunotherapies and COVID-19 related Neurological manifestations: A Comprehensive Review Article. Journal of immunoassay & immunochemistry. 2020 Nov; 41(6):960-975. doi: 10.1080/15321819.2020.1865400. [PMID: 33393415]
  • Marcello De Angelis, Maria Petracca, Roberta Lanzillo, Vincenzo Brescia Morra, Marcello Moccia. Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice. Multiple sclerosis and related disorders. 2020 Oct; 45(?):102452. doi: 10.1016/j.msard.2020.102452. [PMID: 32823148]
  • Wallace J Brownlee. COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?. Multiple sclerosis (Houndmills, Basingstoke, England). 2020 09; 26(10):1267. doi: 10.1177/1352458520948211. [PMID: 32762499]
  • Rick Dersch, Thomas Wehrum, Sebastian Fähndrich, Monika Engelhardt, Sebastian Rauer, Benjamin Berger. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment. Multiple sclerosis (Houndmills, Basingstoke, England). 2020 09; 26(10):1264-1266. doi: 10.1177/1352458520943783. [PMID: 32762488]
  • David Baker, Sandra Amor, Angray S Kang, Klaus Schmierer, Gavin Giovannoni. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. Multiple sclerosis and related disorders. 2020 Aug; 43(?):102174. doi: 10.1016/j.msard.2020.102174. [PMID: 32464584]
  • K Rejdak, S Szklener, A Korchut, D Baranowski. Cladribine in myasthenia gravis: a pilot open-label study. European journal of neurology. 2020 03; 27(3):586-589. doi: 10.1111/ene.14124. [PMID: 31705552]
  • Anna Jamroz-Wiśniewska, Jerzy Bełtowski, Grażyna Wójcicka, Halina Bartosik-Psujek, Konrad Rejdak. Cladribine Treatment Improved Homocysteine Metabolism and Increased Total Serum Antioxidant Activity in Secondary Progressive Multiple Sclerosis Patients. Oxidative medicine and cellular longevity. 2020; 2020(?):1654754. doi: 10.1155/2020/1654754. [PMID: 32256946]
  • Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
  • David Baker, Gareth Pryce, Samuel S Herrod, Klaus Schmierer. Potential mechanisms of action related to the efficacy and safety of cladribine. Multiple sclerosis and related disorders. 2019 May; 30(?):176-186. doi: 10.1016/j.msard.2019.02.018. [PMID: 30785074]
  • Animesh Pardanani. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. American journal of hematology. 2019 03; 94(3):363-377. doi: 10.1002/ajh.25371. [PMID: 30536695]
  • Fabienne Kunz, Evangelia Kontopoulou, Katarina Reinhardt, Maren Soldierer, Sarah Strachan, Dirk Reinhardt, Basant Kumar Thakur. Detection of AML-specific mutations in pediatric patient plasma using extracellular vesicle-derived RNA. Annals of hematology. 2019 03; 98(3):595-603. doi: 10.1007/s00277-019-03608-y. [PMID: 30673813]
  • Robert Hermann, Mats O Karlsson, Ana M Novakovic, Nadia Terranova, Markus Fluck, Alain Munafo. The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis. Clinical pharmacokinetics. 2019 03; 58(3):283-297. doi: 10.1007/s40262-018-0695-9. [PMID: 29987837]
  • Gavin Giovannoni, Chris Hawkes, Michael Levy, Jeannette Lechner-Scott, Emmanuelle Waubant. Should our treatment target in MS include the intrathecal plasma cell response?. Multiple sclerosis and related disorders. 2019 01; 27(?):A1-A2. doi: 10.1016/j.msard.2018.12.039. [PMID: 30642567]
  • Bryan Ceronie, Benjamin M Jacobs, David Baker, Nicolas Dubuisson, Zhifeng Mao, Francesca Ammoscato, Helen Lock, Hilary J Longhurst, Gavin Giovannoni, Klaus Schmierer. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. Journal of neurology. 2018 May; 265(5):1199-1209. doi: 10.1007/s00415-018-8830-y. [PMID: 29550884]
  • Radojka M Savic, Ana M Novakovic, Marianne Ekblom, Alain Munafo, Mats O Karlsson. Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis. Clinical pharmacokinetics. 2017 10; 56(10):1245-1253. doi: 10.1007/s40262-017-0516-6. [PMID: 28255849]
  • Mohamad Jawhar, Juliana Schwaab, Manja Meggendorfer, Nicole Naumann, Hans-Peter Horny, Karl Sotlar, Torsten Haferlach, Karla Schmitt, Alice Fabarius, Peter Valent, Wolf-Karsten Hofmann, Nicholas C P Cross, Georgia Metzgeroth, Andreas Reiter. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. Haematologica. 2017 06; 102(6):1035-1043. doi: 10.3324/haematol.2017.163964. [PMID: 28255023]
  • Steven P Treon. How I treat Waldenström macroglobulinemia. Blood. 2015 Aug; 126(6):721-32. doi: 10.1182/blood-2015-01-553974. [PMID: 26002963]
  • Ilona Tsybulskaya, Tamara Kulak, Elena Kalinichenko, Alexander Baranovsky, Svetlana Bogushevich, Marina Golubeva, Boleslav Kuzmitsky. Phospholipid derivatives of cladribine and fludarabine: synthesis and biological properties. Bioorganic & medicinal chemistry. 2015 Jul; 23(13):3287-96. doi: 10.1016/j.bmc.2015.04.059. [PMID: 25960323]
  • Venkata V V R Marada, Saskia Flörl, Annett Kühne, Gerhard Burckhardt, Yohannes Hagos. Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds. European journal of medicinal chemistry. 2015 Mar; 92(?):723-31. doi: 10.1016/j.ejmech.2015.01.011. [PMID: 25618019]
  • A D Lock, C J McNamara, M H A Rustin. Sustained improvement in urticaria pigmentosa and pruritus in a case of indolent systemic mastocytosis treated with cladribine. Clinical and experimental dermatology. 2015 Mar; 40(2):142-5. doi: 10.1111/ced.12488. [PMID: 25515765]
  • Animesh Pardanani. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management. American journal of hematology. 2015 Mar; 90(3):250-62. doi: 10.1002/ajh.23931. [PMID: 25688753]
  • Jihua Cheng, Giampaolo Talamo, Jozef Malysz, Marlene Ochmann, Thierry Lamy, Thomas P Loughran. Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia. Clinical lymphoma, myeloma & leukemia. 2014 Oct; 14(5):e169-72. doi: 10.1016/j.clml.2014.04.001. [PMID: 25037886]
  • Stefan H P Kraus, Felix Luessi, Bettina Trinschek, Steffen Lerch, Mario Hubo, Laura Poisa-Beiro, Magdalena Paterka, Helmut Jonuleit, Frauke Zipp, Valérie Jolivel. Cladribine exerts an immunomodulatory effect on human and murine dendritic cells. International immunopharmacology. 2014 Feb; 18(2):347-57. doi: 10.1016/j.intimp.2013.11.027. [PMID: 24316255]
  • Holger Scheible, Marc Laisney, Elmar Wimmer, Ana Javornik, Hugues Dolgos. Comparison of the in vitro and in vivo metabolism of Cladribine (Leustatin, Movectro) in animals and human. Xenobiotica; the fate of foreign compounds in biological systems. 2013 Dec; 43(12):1084-94. doi: 10.3109/00498254.2013.791762. [PMID: 23627543]
  • Ella S M Ng, S Bill Kangarloo, Andrew Daly. Improved quantitative method for fludarabine in human plasma by liquid chromatography and tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2013 Jul; 931(?):103-10. doi: 10.1016/j.jchromb.2013.05.012. [PMID: 23777614]
  • Animesh Pardanani. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. American journal of hematology. 2013 Jul; 88(7):612-24. doi: 10.1002/ajh.23459. [PMID: 23720340]
  • Leigh Sutton, Stephanie Sutton, Margaret Sutton. Treatment of necrobiotic xanthogranuloma with 2-chlorodeoxyadenosine. Skinmed. 2013 Mar; 11(2):121-3. doi: NULL. [PMID: 23745232]
  • Tomasz Bączek, Lucyna Konieczna, Mariusz Belka, Lucyna Maciejka-Kapuścińska, Jakub Wiśniewski, Maciej Niedźwiecki, Anna Balcerska, Elżbieta Adamkiewicz-Drożyńska, Jacek Wachowiak. Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis. Journal of pharmaceutical and biomedical analysis. 2012 Nov; 70(?):330-6. doi: 10.1016/j.jpba.2012.05.012. [PMID: 22658903]
  • Philippa L Kohnke, Swetlana Mactier, Juhura G Almazi, Ben Crossett, Richard I Christopherson. Fludarabine and cladribine induce changes in surface proteins on human B-lymphoid cell lines involved with apoptosis, cell survival, and antitumor immunity. Journal of proteome research. 2012 Sep; 11(9):4436-48. doi: 10.1021/pr300079c. [PMID: 22839105]
  • Animesh Pardanani. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management. American journal of hematology. 2012 Apr; 87(4):401-11. doi: 10.1002/ajh.23134. [PMID: 22410759]
  • Crystal D Hayes, Debleena Dey, Juan Pablo Palavicini, Hongjie Wang, Wataru Araki, Madepalli K Lakshmana. Chronic cladribine administration increases amyloid beta peptide generation and plaque burden in mice. PloS one. 2012; 7(10):e45841. doi: 10.1371/journal.pone.0045841. [PMID: 23056220]
  • James B Johnston. Mechanism of action of pentostatin and cladribine in hairy cell leukemia. Leukemia & lymphoma. 2011 Jun; 52 Suppl 2(?):43-5. doi: 10.3109/10428194.2011.570394. [PMID: 21463108]
  • Andrzej Mital, Anna Piskorz, Krzysztof Lewandowski, Bartosz Wasąg, Janusz Limon, Andrzej Hellmann. A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. European journal of haematology. 2011 Jun; 86(6):531-5. doi: 10.1111/j.1600-0609.2011.01598.x. [PMID: 21362052]
  • Michael Kovochich, Matthew D Marsden, Jerome A Zack. Activation of latent HIV using drug-loaded nanoparticles. PloS one. 2011 Apr; 6(4):e18270. doi: 10.1371/journal.pone.0018270. [PMID: 21483687]
  • Farzaneh Khezri, Lawrence E Gibson, Ayalew Tefferi. Xanthoma disseminatum: effective therapy with 2-chlorodeoxyadenosine in a case series. Archives of dermatology. 2011 Apr; 147(4):459-64. doi: 10.1001/archdermatol.2010.378. [PMID: 21173305]
  • Animesh Pardanani. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management. American journal of hematology. 2011 Apr; 86(4):362-71. doi: 10.1002/ajh.21982. [PMID: 21442641]
  • Michael R Grever, Gerard Lozanski. Modern strategies for hairy cell leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Feb; 29(5):583-90. doi: 10.1200/jco.2010.31.7016. [PMID: 21220590]
  • Monika Podhorecka, Dorota Halicka, Piotr Klimek, Malgorzata Kowal, Sylwia Chocholska, Anna Dmoszynska. Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia. Annals of hematology. 2011 Feb; 90(2):173-83. doi: 10.1007/s00277-010-1045-7. [PMID: 20714724]
  • Shannon Mulligan, P Hu, A Murphy, J Han, M Tam, P Lin, S Konoplev, P A Lennon. Variations in MALT1 Gene Disruptions Detected by FISH in 109 MALT Lymphomas Occurring in Different Primary Sites. Journal of the Association of Genetic Technologists. 2011; 37(2):76-9. doi: . [PMID: 21654070]
  • Sanjay Kumar, Kavindra Kumar Kesari, Jitendra Behari. The therapeutic effect of a pulsed electromagnetic field on the reproductive patterns of male Wistar rats exposed to a 2.45-GHz microwave field. Clinics (Sao Paulo, Brazil). 2011; 66(7):1237-45. doi: 10.1590/s1807-59322011000700020. [PMID: 21876981]
  • Cindy Castrale, Wael El Haggan, Françoise Chapon, Oumedaly Reman, Thierry Lobbedez, Jean Philippe Ryckelynck, Bruno Hurault de Ligny. Lymphomatoid granulomatosis treated successfully with rituximab in a renal transplant patient. Journal of transplantation. 2011; 2011(?):865957. doi: 10.1155/2011/865957. [PMID: 21559262]
  • Yin-Quan Tang, Indu Bala Jaganath, Shamala Devi Sekaran. Phyllanthus spp. induces selective growth inhibition of PC-3 and MeWo human cancer cells through modulation of cell cycle and induction of apoptosis. PloS one. 2010 Sep; 5(9):e12644. doi: 10.1371/journal.pone.0012644. [PMID: 20838625]
  • Ulrich Amon, Karin Hartmann, Hans-Peter Horny, Anna Nowak. Mastocytosis - an update. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2010 Sep; 8(9):695-711; quiz 712. doi: 10.1111/j.1610-0387.2010.07482.x. [PMID: 20678151]
  • Alexandra Böhm, Karoline Sonneck, Karoline V Gleixner, Karina Schuch, Winfried F Pickl, Katharina Blatt, Barbara Peter, Harald Herrmann, Gerit-Holger Schernthaner, Hubert Pehamberger, Werner Rabitsch, Wolfgang R Sperr, Peter Valent. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Experimental hematology. 2010 Sep; 38(9):744-55. doi: 10.1016/j.exphem.2010.05.006. [PMID: 20553795]
  • Zdeněk Adam, Jiří Mašlaň, Leoš Křen, Roman Kodet, Renata Koukalová, Zdeněk Řehák, Libor Červinek, Luděk Pour, Marta Krejčí, Viera Sandecká, Zdeněk Král, Jiří Mayer. [Sinus histiocytosis with massive lymphadenopathy: FDG-PET/CT documented partial remission after treatment with 2-chlorodeoxyadenosine]. Vnitrni lekarstvi. Summ r 2; 62(6):491-9. doi: NULL. [PMID: 27485849]
  • Małgorzata Rogalińska, Jerzy Z Błoński, Oxana Komina, Paweł Góralski, Jolanta D Zołnierczyk, Henryk Piekarski, Tadeusz Robak, Zofia M Kiliańska, Józefa Wesierska-Gadek. R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis. Journal of cellular biochemistry. 2010 Jan; 109(1):217-35. doi: 10.1002/jcb.22400. [PMID: 19911397]
  • Patricia Hentosh, Dennis M Peffley. The cladribine conundrum: deciphering the drug's mechanism of action. Expert opinion on drug metabolism & toxicology. 2010 Jan; 6(1):75-81. doi: 10.1517/17425250903393745. [PMID: 19968576]
  • Thomas Borrmann, Aliaa Abdelrahman, Rosaria Volpini, Catia Lambertucci, Edgars Alksnis, Simone Gorzalka, Melanie Knospe, Anke C Schiedel, Gloria Cristalli, Christa E Müller. Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family. Journal of medicinal chemistry. 2009 Oct; 52(19):5974-89. doi: 10.1021/jm9006356. [PMID: 19731917]
  • Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance. Journal of medicinal chemistry. 2009 Aug; 52(15):4844-52. doi: 10.1021/jm900403j. [PMID: 19445515]
  • Jianmin Wang, Shuqing Lü, Jianmin Yang, Xianmin Song, Li Chen, Chongmei Huang, Jun Hou, Weiping Zhang. A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China. Journal of hematology & oncology. 2009 Jul; 2(?):32. doi: 10.1186/1756-8722-2-32. [PMID: 19642997]
  • Kensei Tobinai, Takashi Watanabe, Kazuki Tanimoto, Dai Maruyama, Masanobu Nakata, Kuniaki Itoh, Yasuo Morishima, Michinori Ogura, Noriko Usui, Masaharu Kasai, Takashi Terauchi, Shigeru Nawano, Masaki Matsusako, Yoshihiro Matsuno, Shigeo Nakamura, Shigeo Mori, Yasuo Ohashi. Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab. Cancer science. 2009 Jul; 100(7):1344-50. doi: 10.1111/j.1349-7006.2009.01162.x. [PMID: 19432900]
  • Adam N Elwi, Vijaya L Damaraju, Michelle L Kuzma, Delores A Mowles, Stephen A Baldwin, James D Young, Michael B Sawyer, Carol E Cass. Transepithelial fluxes of adenosine and 2'-deoxyadenosine across human renal proximal tubule cells: roles of nucleoside transporters hENT1, hENT2, and hCNT3. American journal of physiology. Renal physiology. 2009 Jun; 296(6):F1439-51. doi: 10.1152/ajprenal.90411.2008. [PMID: 19297449]
  • Josa M Frischer, Stephan Bramow, Assunta Dal-Bianco, Claudia F Lucchinetti, Helmut Rauschka, Manfred Schmidbauer, Henning Laursen, Per Soelberg Sorensen, Hans Lassmann. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain : a journal of neurology. 2009 May; 132(Pt 5):1175-89. doi: 10.1093/brain/awp070. [PMID: 19339255]
  • Luke H Stockwin, Sherry X Yu, Howard Stotler, Melinda G Hollingshead, Dianne L Newton. ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC. BMC cancer. 2009 Feb; 9(?):63. doi: 10.1186/1471-2407-9-63. [PMID: 19232100]
  • Aldo M Roccaro, Irene M Ghobrial, Simona Blotta, Steven P Treon, Michele Malagola, Kenneth C Anderson, Paul G Richardson, Domenico Russo. Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias. Biologics : targets & therapy. 2008 Sep; 2(3):419-31. doi: 10.2147/btt.s3088. [PMID: 19707373]
  • Qi-qi Jiang, Lin-yu Fan, Guang-li Yang, Wen-Hao Guo, Wen-li Hou, Li-juan Chen, Yu-quan Wei. Improved therapeutic effectiveness by combining liposomal honokiol with cisplatin in lung cancer model. BMC cancer. 2008 Aug; 8(?):242. doi: 10.1186/1471-2407-8-242. [PMID: 18706101]
  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • Hongjie Li, Gromoslaw A Smolen, Lisa F Beers, Li Xia, William Gerald, Joanne Wang, Daniel A Haber, Sean Bong Lee. Adenosine transporter ENT4 is a direct target of EWS/WT1 translocation product and is highly expressed in desmoplastic small round cell tumor. PloS one. 2008 Jun; 3(6):e2353. doi: 10.1371/journal.pone.0002353. [PMID: 18523561]
  • Jerzy Hołowiecki, Sebastian Grosicki, Sławomira Kyrcz-Krzemien, Aleksander B Skotnicki, Beata Piatkowska-Jakubas, Krzysztof Warzocha, Ilona Seferynska, Barbara Zdziarska. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study. Annals of hematology. 2008 May; 87(5):361-7. doi: 10.1007/s00277-007-0421-4. [PMID: 18074133]
  • Vk Kimiskidis, I Sakellari, V Tsimourtou, V Kapina, S Papagiannopoulos, D Kazis, N Vlaikidis, A Anagnostopoulos, A Fassas. Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome. Multiple sclerosis (Houndmills, Basingstoke, England). 2008 Mar; 14(2):278-83. doi: 10.1177/1352458507082604. [PMID: 17942513]
  • Pollen K F Yeung, Brian King, Soulatchana Narayanan, Mary Le Min Li. Pharmacokinetics of cladribine in a rat model following subcutaneous and intra-arterial injections. Drug metabolism and drug interactions. 2008; 23(3-4):291-8. doi: 10.1515/dmdi.2008.23.3-4.291. [PMID: 19326772]
  • Til Menge, Martin S Weber, Bernhard Hemmer, Bernd C Kieseier, Hans-Christian von Büdingen, Clemens Warnke, Scott S Zamvil, Aaron Boster, Omar Khan, Hans-Peter Hartung, Olaf Stüve. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs. 2008; 68(17):2445-68. doi: 10.2165/0003495-200868170-00004. [PMID: 19016573]
  • G Dinçol, O Doğan, R-D Küçükkaya, E Gül, R Kahraman, M Ağan. Hairy cell leukaemia presenting with ascites, pleural effusion and increased CA 125 serum level. The Netherlands journal of medicine. 2008 Jan; 66(1):23-6. doi: NULL. [PMID: 18219064]
  • Yunsheng Hsieh, Christine J G Duncan, Suining Lee, Ming Liu. Comparison of fast liquid chromatography/tandem mass spectrometric methods for simultaneous determination of cladribine and clofarabine in mouse plasma. Journal of pharmaceutical and biomedical analysis. 2007 Jun; 44(2):492-7. doi: 10.1016/j.jpba.2007.02.007. [PMID: 17368998]
  • Anna Fyrberg, Freidoun Albertioni, Kourosh Lotfi. Cell cycle effect on the activity of deoxynucleoside analogue metabolising enzymes. Biochemical and biophysical research communications. 2007 Jun; 357(4):847-53. doi: 10.1016/j.bbrc.2007.03.176. [PMID: 17459340]
  • Davide Rossi, Silvia Franceschetti, Michaela Cerri, Annarita Conconi, Monia Lunghi, Daniela Capello, Roberto Cantello, Gianluca Gaidano. Hairy cell leukaemia complicated by anti-MAG paraproteinemic demyelinating neuropathy: resolution of neurological syndrome after cladribrine treatment. Leukemia research. 2007 Jun; 31(6):873-6. doi: 10.1016/j.leukres.2006.08.020. [PMID: 17007925]
  • Mrinal M Patnaik, Michelle Rindos, Peter A Kouides, Ayalew Tefferi, Animesh Pardanani. Systemic mastocytosis: a concise clinical and laboratory review. Archives of pathology & laboratory medicine. 2007 May; 131(5):784-91. doi: 10.5858/2007-131-784-smacca. [PMID: 17488167]
  • Bih Fang Pan, J Arly Nelson. Dihydrodiol dehydrogenase in drug resistance and sensitivity of human carcinomas. Cancer chemotherapy and pharmacology. 2007 Apr; 59(5):697-702. doi: 10.1007/s00280-006-0351-1. [PMID: 17009030]
  • Tomasz Kryczka, Zygmunt Kazimierczuk, Mariola Kozłowska, Stanisław J Chrapusta, Leena Vilpo, Juhani Vilpo, Krzysztof Stachnik, Monika Janisz, Paweł Grieb. Two novel nucleoside ester derivatives of chlorambucil as potential antileukemic prodrugs: a preliminary study. Anti-cancer drugs. 2007 Mar; 18(3):301-10. doi: 10.1097/cad.0b013e328011512d. [PMID: 17264763]
  • Li Xia, Karen Engel, Mingyan Zhou, Joanne Wang. Membrane localization and pH-dependent transport of a newly cloned organic cation transporter (PMAT) in kidney cells. American journal of physiology. Renal physiology. 2007 Feb; 292(2):F682-90. doi: 10.1152/ajprenal.00302.2006. [PMID: 17018840]
  • Robert S Jansen, Hilde Rosing, Cocky J F de Wolf, Jos H Beijnen. Development and validation of an assay for the quantitative determination of cladribine nucleotides in MDCKII cells and culture medium using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. Rapid communications in mass spectrometry : RCM. 2007; 21(24):4049-59. doi: 10.1002/rcm.3318. [PMID: 18008286]
  • Pollen K F Yeung, Carrie Ferguson, Ameer Jarrar, Brian King, Mary L Li. Development and validation of a sensitive and specific HPLC assay of cladribine for pharmacokinetics studies in rats. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 2007; 10(2):231-6. doi: NULL. [PMID: 17706181]
  • Eriko Takahashi, Osamu Inanami, Toshio Ohta, Akira Matsuda, Mikinori Kuwabara. Lipid raft disruption prevents apoptosis induced by 2-chloro-2'-deoxyadenosine (Cladribine) in leukemia cell lines. Leukemia research. 2006 Dec; 30(12):1555-61. doi: 10.1016/j.leukres.2006.04.008. [PMID: 16730061]
  • Ryan P Owen, Ilaria Badagnani, Kathleen M Giacomini. Molecular determinants of specificity for synthetic nucleoside analogs in the concentrative nucleoside transporter, CNT2. The Journal of biological chemistry. 2006 Sep; 281(36):26675-82. doi: 10.1074/jbc.m513421200. [PMID: 16840788]
  • Yutaka Okawa, Takaki Shimada, Eijirou Nagasaki, Akiyo Nozato, Fumi Mizoroki, Masayuki Kobayashi. [Pulmonary cryptococcosis occurring 6 months after cladribine therapy for relapsed follicular lymphoma]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2006 Jul; 47(7):650-5. doi: NULL. [PMID: 16910576]
  • S A Johnson, J Birchall, C Luckie, D G Oscier, R G Owen. Guidelines on the management of Waldenström macroglobulinaemia. British journal of haematology. 2006 Mar; 132(6):683-97. doi: 10.1111/j.1365-2141.2005.05948.x. [PMID: 16487169]
  • Karen M King, Vijaya L Damaraju, Mark F Vickers, Sylvia Y Yao, Thach Lang, Tracey E Tackaberry, Delores A Mowles, Amy M L Ng, James D Young, Carol E Cass. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Molecular pharmacology. 2006 Jan; 69(1):346-53. doi: 10.1124/mol.105.015768. [PMID: 16234483]
  • Olivier Fain, Jerôme Stirnemann, Olivier Lortholary. [Systemic mastocytosis]. La Revue du praticien. 2005 Oct; 55(15):1629-36. doi: NULL. [PMID: 16334197]
  • O Fain, J Stirnemann, V Eclache, S Barete, P Casassus, O Hermine, O Lorholary. [Systemic mastocytosis]. Presse medicale (Paris, France : 1983). 2005 May; 34(9):681-7. doi: 10.1016/s0755-4982(05)84013-8. [PMID: 15988348]
  • Stephen A Baldwin, Sylvia Y M Yao, Ralph J Hyde, Amy M L Ng, Sophie Foppolo, Kay Barnes, Mabel W L Ritzel, Carol E Cass, James D Young. Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. The Journal of biological chemistry. 2005 Apr; 280(16):15880-7. doi: 10.1074/jbc.m414337200. [PMID: 15701636]